These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 20437404

  • 1. Urinary monocyte chemotactic protein 1: marker of renal function decline in diabetic and nondiabetic proteinuric renal disease.
    Camilla R, Brachemi S, Pichette V, Cartier P, Laforest-Renald A, MacRae T, Madore F, Troyanov S.
    J Nephrol; 2011; 24(1):60-7. PubMed ID: 20437404
    [Abstract] [Full Text] [Related]

  • 2. Clinical value of inflammatory urinary biomarkers in overt diabetic nephropathy: a prospective study.
    Verhave JC, Bouchard J, Goupil R, Pichette V, Brachemi S, Madore F, Troyanov S.
    Diabetes Res Clin Pract; 2013 Sep; 101(3):333-40. PubMed ID: 23880038
    [Abstract] [Full Text] [Related]

  • 3. Associations of urinary epidermal growth factor and monocyte chemotactic protein-1 with kidney involvement in patients with diabetic kidney disease.
    Wu L, Li XQ, Chang DY, Zhang H, Li JJ, Wu SL, Zhang LX, Chen M, Zhao MH.
    Nephrol Dial Transplant; 2020 Feb 01; 35(2):291-297. PubMed ID: 30357416
    [Abstract] [Full Text] [Related]

  • 4. Urinary epidermal growth factor, monocyte chemoattractant protein-1 or their ratio as predictors for rapid loss of renal function in type 2 diabetic patients with diabetic kidney disease.
    Satirapoj B, Dispan R, Radinahamed P, Kitiyakara C.
    BMC Nephrol; 2018 Sep 21; 19(1):246. PubMed ID: 30241508
    [Abstract] [Full Text] [Related]

  • 5. Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.
    Nowak N, Skupien J, Smiles AM, Yamanouchi M, Niewczas MA, Galecki AT, Duffin KL, Breyer MD, Pullen N, Bonventre JV, Krolewski AS.
    Kidney Int; 2018 May 21; 93(5):1198-1206. PubMed ID: 29398132
    [Abstract] [Full Text] [Related]

  • 6. Transforming growth factor beta 1 and monocyte chemoattractant protein-1 as prognostic markers of diabetic nephropathy.
    Shaker OG, Sadik NA.
    Hum Exp Toxicol; 2013 Oct 21; 32(10):1089-96. PubMed ID: 23515495
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Increased urinary excretion of monocyte chemoattractant protein-1 in proteinuric renal diseases.
    Morii T, Fujita H, Narita T, Koshimura J, Shimotomai T, Fujishima H, Yoshioka N, Imai H, Kakei M, Ito S.
    Ren Fail; 2003 May 21; 25(3):439-44. PubMed ID: 12803507
    [Abstract] [Full Text] [Related]

  • 9. Nephrotic range proteinuria as a strong risk factor for rapid renal function decline during pre-dialysis phase in type 2 diabetic patients with severely impaired renal function.
    Kitai Y, Doi Y, Osaki K, Sugioka S, Koshikawa M, Sugawara A.
    Clin Exp Nephrol; 2015 Dec 21; 19(6):1037-43. PubMed ID: 25680889
    [Abstract] [Full Text] [Related]

  • 10. Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy.
    Tam FW, Riser BL, Meeran K, Rambow J, Pusey CD, Frankel AH.
    Cytokine; 2009 Jul 21; 47(1):37-42. PubMed ID: 19409809
    [Abstract] [Full Text] [Related]

  • 11. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases.
    Chen YM, Lin SL, Chiang WC, Wu KD, Tsai TJ.
    Kidney Int; 2006 Apr 21; 69(8):1410-5. PubMed ID: 16541021
    [Abstract] [Full Text] [Related]

  • 12. Renal TLR4 mRNA expression correlates with inflammatory marker MCP-1 and profibrotic molecule TGF-β₁ in patients with chronic kidney disease.
    Lepenies J, Eardley KS, Kienitz T, Hewison M, Ihl T, Stewart PM, Cockwell P, Quinkler M.
    Nephron Clin Pract; 2011 Apr 21; 119(2):c97-c104. PubMed ID: 21677444
    [Abstract] [Full Text] [Related]

  • 13. Urinary MCP-1 and RBP: independent predictors of renal outcome in macroalbuminuric diabetic nephropathy.
    Titan SM, Vieira JM, Dominguez WV, Moreira SR, Pereira AB, Barros RT, Zatz R.
    J Diabetes Complications; 2012 Apr 21; 26(6):546-53. PubMed ID: 22981148
    [Abstract] [Full Text] [Related]

  • 14. Measurement of urinary TGF-β1 in patients with diabetes mellitus and normal controls.
    Tsapenko MV, Nwoko RE, Borland TM, Voskoboev NV, Pflueger A, Rule AD, Lieske JC.
    Clin Biochem; 2013 Oct 21; 46(15):1430-5. PubMed ID: 23685222
    [Abstract] [Full Text] [Related]

  • 15. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
    Messchendorp AL, Meijer E, Visser FW, Engels GE, Kappert P, Losekoot M, Peters DJM, Gansevoort RT, on behalf of the DIPAK-1 study investigators.
    Am J Nephrol; 2019 Oct 21; 50(5):375-385. PubMed ID: 31600749
    [Abstract] [Full Text] [Related]

  • 16. Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy.
    Morii T, Fujita H, Narita T, Shimotomai T, Fujishima H, Yoshioka N, Imai H, Kakei M, Ito S.
    J Diabetes Complications; 2003 Oct 21; 17(1):11-5. PubMed ID: 12505750
    [Abstract] [Full Text] [Related]

  • 17. Value of urinary levels of interleukin-6, epidermal growth factor, monocyte chemoattractant protein type1 and transforming growth factor β1 in predicting the extent of fibrosis lesions in kidney biopsies of patients with IgA nephropathy.
    Segarra-Medrano A, Carnicer-Caceres C, Valtierra-Carmeno N, Agraz-Pamplona I, Ramos-Terrades N, Jatem Escalante E, Ostos-Roldan E.
    Nefrologia; 2017 Oct 21; 37(5):531-538. PubMed ID: 28946966
    [Abstract] [Full Text] [Related]

  • 18. Urinary kallikrein excretion is related to renal function change and inflammatory status in chronic kidney disease patients receiving angiotensin II receptor blocker treatment.
    Chiang WC, Lin SL, Chen YM, Wu KD, Tsai TJ.
    Nephrology (Carlton); 2008 Jun 21; 13(3):198-203. PubMed ID: 18315702
    [Abstract] [Full Text] [Related]

  • 19. Sodium Bicarbonate Supplementation and Urinary TGF-β1 in Nonacidotic Diabetic Kidney Disease: A Randomized, Controlled Trial.
    Raphael KL, Greene T, Wei G, Bullshoe T, Tuttle K, Cheung AK, Beddhu S.
    Clin J Am Soc Nephrol; 2020 Feb 07; 15(2):200-208. PubMed ID: 31974286
    [Abstract] [Full Text] [Related]

  • 20. Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic nephropathy.
    Mise K, Hoshino J, Ueno T, Hazue R, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Suwabe T, Sawa N, Fujii T, Hara S, Ohashi K, Takaichi K, Ubara Y.
    Diabetes Metab Res Rev; 2015 Sep 07; 31(6):572-81. PubMed ID: 25533683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.